| The efficacy and safety of extending the ischemic time with a modified cardioplegic technique for coronary artery surgery. | |
| | |
MedLine Citation:
|
PMID: 18928483 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND AND AIM: The need to intermittently discontinue the administration of cardioplegia in order to complete the surgical procedure is a major drawback of antegrade warm blood cardioplegia. An ischemic time of 15 minutes is generally considered safe based on empirical observation. The aim of this study was the evaluation of the efficacy and safety of an intermittent warm blood cardioplegia with intervals between administrations prolonged to 25 minutes. METHODS: Ninety-seven patients undergoing primary elective coronary artery revascularization were prospectively randomized into two groups. The first, Intermittent Antegrade Warm Blood Cardioplegia (IAWBC) group, comprising 49 patients, received standard intermittent antegrade warm blood cardioplegia repeated every 15 minutes. The second, Modified Intermittent Antegrade Warm Blood Cardioplegia (M-IAWBC) group, comprising 48 patients, received intermittent antegrade warm blood cardioplegia supplemented with magnesium sulfate (MgSO(4)), delivered in volumes proportional to the ventricular mass and repeated every 25 minutes. The clinical outcomes were evaluated. The levels of creatine kinase-MB (CK-MB) isoenzyme, in addition to the echocardiographic assessment of septal dyskinesia and tricuspid annulus plane systolic excursion (TAPSE), have been used as markers of myocardial damage. RESULTS: There were no statistically significant differences in clinical outcomes, need for inotropes and vasodilators, length of stay in the intensive care unit, and postoperative levels of CK-MB between the two groups. Likewise, postoperative echocardiographic assessment showed no relevant differences. CONCLUSIONS: Administration of warm antegrade cardioplegic solution supplemented with MgSO(4), delivered in volumes proportional to ventricular mass every 25 minutes, provides adequate myocardial protection for coronary artery surgery. |
| | |
Authors:
|
Stefano Casalino; Ugo F Tesler; Eugenio Novelli; Edmond Stelian; Luca Renzi; Claudio Alessi; Guido Lanzillo; Gheorghe Cerin; Marco Diena |
Related Documents
:
|
9316543 - Reduced sympathetic innervation underlies adjacent noninfarcted region dysfunction duri... 15665053 - Impaired resting perfusion in viable myocardium distal to chronic coronary stenosis in ... 15311643 - Antibiotic sampling from central venous catheters versus peripheral veins. |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: Journal of cardiac surgery Volume: 23 ISSN: 1540-8191 ISO Abbreviation: J Card Surg Publication Date: 2008 Sep-Oct |
Date Detail:
|
Created Date: 2008-10-20 Completed Date: 2009-03-03 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8908809 Medline TA: J Card Surg Country: United States |
Other Details:
|
Languages: eng Pagination: 444-9 Citation Subset: IM |
Affiliation:
|
Department of Anesthesiology, Casa di Cura San Gaudenzio, Novara, Italy. casalino63@libero.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Biological Markers / blood Body Temperature Cardioplegic Solutions Cardiotonic Agents / therapeutic use Cardiovascular Surgical Procedures / adverse effects, methods* Coronary Artery Disease / surgery*, ultrasonography Creatine Kinase, MB Form / blood* Female Heart Arrest, Induced / adverse effects*, methods* Humans Length of Stay Male Myocardial Ischemia / physiopathology* Myocardial Revascularization Prospective Studies Time Factors Vasodilator Agents / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers; 0/Cardioplegic Solutions; 0/Cardiotonic Agents; 0/Vasodilator Agents; EC 2.7.3.2/Creatine Kinase, MB Form |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The effects of simultaneous antegrade/retrograde cardioplegia on cellular volumes and energy metabol...
Next Document: Kinetic of procalcitonin in the early postoperative course following heart transplantation.